4/18
02:03 am
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
4/15
08:31 am
onvo
Organovo's fatty liver disease drug meets main goal in mid-stage study [Reuters]
Medium
Report
Organovo's fatty liver disease drug meets main goal in mid-stage study [Reuters]
4/15
08:13 am
onvo
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo [Financial Post (Toronto, Ontario, Canada)
Low
Report
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo [Financial Post (Toronto, Ontario, Canada)
4/15
08:07 am
onvo
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo [Yahoo! Finance]
Medium
Report
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo [Yahoo! Finance]
4/15
08:05 am
onvo
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
High
Report
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
4/10
02:01 am
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
4/2
02:04 am
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Neutral
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/25
02:05 am
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/17
02:02 am
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/9
02:07 am
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/1
02:03 am
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Neutral
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
2/12
10:04 pm
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) was upgraded by analysts at StockNews.com to a "sell" rating.
High
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) was upgraded by analysts at StockNews.com to a "sell" rating.
2/10
09:58 am
onvo
Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
High
Report
Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
2/1
07:11 am
onvo
4D Printing in Healthcare Market projected to reach USD 47.5 Million by 2030, growing at a CAGR of 22.3% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study [Yahoo! Finance]
Low
Report
4D Printing in Healthcare Market projected to reach USD 47.5 Million by 2030, growing at a CAGR of 22.3% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study [Yahoo! Finance]
1/30
10:24 am
onvo
3D Bioprinting Market Global Forecast to 2030, Featuring EnvisionTEC, Organovo, Inventia Life Science, Poietis, Vivax Bio, Allevi, Cyfuse Biomedical, 3D Bioprinting Solutions & Cellink Global [Yahoo! Finance]
Medium
Report
3D Bioprinting Market Global Forecast to 2030, Featuring EnvisionTEC, Organovo, Inventia Life Science, Poietis, Vivax Bio, Allevi, Cyfuse Biomedical, 3D Bioprinting Solutions & Cellink Global [Yahoo! Finance]
1/30
07:44 am
onvo
3D-Printed Organs Market Projected to Reach USD 2.13 Billion by 2030 – New Research Highlights Trends, Technologies and Regional Growth [Yahoo! Finance]
Low
Report
3D-Printed Organs Market Projected to Reach USD 2.13 Billion by 2030 – New Research Highlights Trends, Technologies and Regional Growth [Yahoo! Finance]
1/25
08:18 am
onvo
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress [Yahoo! Finance]
Medium
Report
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress [Yahoo! Finance]
1/25
08:14 am
onvo
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress [Financial Post (Toronto, Ontario, Canada)]
1/25
08:05 am
onvo
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
Medium
Report
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress